press release-凯发88

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

news press release media report

year:

select

press release

19 november 2018

alphamab oncology completes series-a round financing - further strengthening its global innovative biologics platforms alphamab oncology announced the successful completion of series a financing round, with more than $100 million raised. a number of well-regarded institutional investors, including advantech capital, p...
24 october 2018

kn035, a global leading subcutaneously-administered pd-l1 antibody, starts late-stage clinical development；kn035's us phase i clinical data was presented at the annual esmo congress suzhou, china, oct. 23, 2018 /prnewswire/ -- alphamab oncology and 3d medicines inc. (3d med) announced today pd-l1 antibody kn035 has entered late stage clinical development
16 october 2018

alphamab oncology's her2 bispecific antibody kn026 gained us ind approval; phase i clinical trial started in china suzhou, china, oct. 16, 2018 /prnewswire/ -- alphamab oncology announced that it has received us fda's ind approval for its proprietary her2 bispecific antibody (product code: kn026), and kn026 ...
10 october 2018

alphamab oncology's first-in-class pd-l1 - ctla-4 bispecific antibody kn046 enters clinical trial alphamab oncology announced that its proprietary humanized pd-l1 - ctla-4 bispecific antibody (product code: kn046) program, the first of its class, has recently started phase i clinical trial in aust...
13 april 2018

alphamab’s novel her-2 bispecific antibody kn026 gains ind approval in china; cmc validation of its proprietary bispecific platform suzhou, china--(business wire)-suzhou alphamab co., ltd. announced today that the ind for its leading bispecific program kn026 has been approved by the cfda, marking a significant milestone for alpham...
30 november 2016

global first ind for subcutaneous injectable anti-pd-l1 domain antibody receives fda approval suzhou, china & chengdu, china--(business wire)-3d medicines (sichuan) co., ltd. and suzhou alphamab co., ltd. announced today that the u.s. fda has completed its review of the ind for their drug kn03...

prev12/12